Abemaciclib after local recurrence in HR+ HER2- breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether adding a targeted drug (abemaciclib) to standard treatment helps prevent breast cancer from coming back again after a local recurrence in women with HR-positive, HER2-negative breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- This is the first time your breast cancer has come back in the same area (breast, chest wall, or nearby lymph nodes).
- The cancer cells are hormone receptor-positive (HR+) and HER2-negative.
- You have not taken a CDK4/6 inhibitor (like Ibrance, Kisqali, or Verzenio) before.
- You have no signs of cancer spread to other organs (distant metastasis).
- You are 18 or older and able to care for yourself (ECOG 0 or 1).
- No serious heart, lung, or liver problems, and no active infection or fever.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
This trial tests whether adding a targeted therapy (abemaciclib) to standard chemotherapy before surgery can shrink tumors and improve outcomes in hormone-positive, HER2-negative early breast cancer. It also uses a genetic test (Oncotype DX) to help guide surgical choices.
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
This trial tests a drug called abemaciclib for people with early-stage, hormone-receptor-positive, HER2-negative breast cancer who still have cancer DNA in their blood after completing standard treatment. It aims to see if taking this drug can reduce the chance of cancer coming back.
This study tests whether women with early-stage HR+/HER2- breast cancer can safely take a higher dose of the drug abemaciclib (Verzenio) after surgery. The goal is to keep the treatment as strong as possible while managing side effects.
This Phase 2 trial tests whether abemaciclib plus hydroxychloroquine can kill tiny “leftover” cancer cells in the bone marrow after standard breast cancer treatment. It may help lower the chance of cancer coming back by targeting minimal residual disease.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.